- Home
- ATHA vs RVYL Comparison
ATHA vs RVYL Comparison
Compare ATHA & RVYL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- RVYL
- Stock Information
- Founded
- ATHA 2011
- RVYL 2007
- Country
- ATHA United States
- RVYL United States
- Employees
- ATHA N/A
- RVYL N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- RVYL Professional Services
- Sector
- ATHA Health Care
- RVYL Consumer Discretionary
- Exchange
- ATHA Nasdaq
- RVYL Nasdaq
- Market Cap
- ATHA 10.6M
- RVYL 10.3M
- IPO Year
- ATHA 2020
- RVYL N/A
- Fundamental
- Price
- ATHA $0.42
- RVYL $0.66
- Analyst Decision
- ATHA Buy
- RVYL Hold
- Analyst Count
- ATHA 4
- RVYL 1
- Target Price
- ATHA $11.25
- RVYL N/A
- AVG Volume (30 Days)
- ATHA 239.8K
- RVYL 779.0K
- Earning Date
- ATHA 07-31-2025
- RVYL 08-12-2025
- Dividend Yield
- ATHA N/A
- RVYL N/A
- EPS Growth
- ATHA N/A
- RVYL N/A
- EPS
- ATHA N/A
- RVYL N/A
- Revenue
- ATHA N/A
- RVYL $54,357,000.00
- Revenue This Year
- ATHA N/A
- RVYL $27.50
- Revenue Next Year
- ATHA N/A
- RVYL $35.71
- P/E Ratio
- ATHA N/A
- RVYL N/A
- Revenue Growth
- ATHA N/A
- RVYL N/A
- 52 Week Low
- ATHA $0.22
- RVYL $0.36
- 52 Week High
- ATHA $3.67
- RVYL $2.40
- Technical
- Relative Strength Index (RSI)
- ATHA 73.73
- RVYL 43.93
- Support Level
- ATHA $0.29
- RVYL $0.60
- Resistance Level
- ATHA $0.32
- RVYL $0.75
- Average True Range (ATR)
- ATHA 0.03
- RVYL 0.10
- MACD
- ATHA 0.01
- RVYL -0.01
- Stochastic Oscillator
- ATHA 78.16
- RVYL 7.89
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About RVYL Ryvyl Inc.
Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.